214 related articles for article (PubMed ID: 24196790)
1. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
2. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
3. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
4. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
5. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
6. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
7. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector.
Ho IA; Hui KM; Lam PY
Hum Gene Ther; 2004 May; 15(5):495-508. PubMed ID: 15144579
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
9. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
[TBL] [Abstract][Full Text] [Related]
10. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
12. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells.
Wang GY; Ho IA; Sia KC; Miao L; Hui KM; Lam PY
Hum Gene Ther; 2007 Mar; 18(3):222-31. PubMed ID: 17355186
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
15. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
18. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas.
Lam PY; Sia KC; Khong JH; De Geest B; Lim KS; Ho IA; Wang GY; Miao LV; Huynh H; Hui KM
Mol Ther; 2007 Jun; 15(6):1129-36. PubMed ID: 17426711
[TBL] [Abstract][Full Text] [Related]
19. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
20. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.
Advani SJ; Markert JM; Sood RF; Samuel S; Gillespie GY; Shao MY; Roizman B; Weichselbaum RR
Gene Ther; 2011 Nov; 18(11):1098-102. PubMed ID: 21544094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]